DE69839215T2 - Dendritische zellhybride - Google Patents

Dendritische zellhybride Download PDF

Info

Publication number
DE69839215T2
DE69839215T2 DE69839215T DE69839215T DE69839215T2 DE 69839215 T2 DE69839215 T2 DE 69839215T2 DE 69839215 T DE69839215 T DE 69839215T DE 69839215 T DE69839215 T DE 69839215T DE 69839215 T2 DE69839215 T2 DE 69839215T2
Authority
DE
Germany
Prior art keywords
cells
cell
cancer
fused
muc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839215T
Other languages
German (de)
English (en)
Other versions
DE69839215D1 (de
Inventor
Jianlin Brookline GONG
Donald Wellesley KUFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of DE69839215D1 publication Critical patent/DE69839215D1/de
Application granted granted Critical
Publication of DE69839215T2 publication Critical patent/DE69839215T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Photovoltaic Devices (AREA)
DE69839215T 1997-04-15 1998-04-15 Dendritische zellhybride Expired - Lifetime DE69839215T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4360997P 1997-04-15 1997-04-15
US43609P 1997-04-15
PCT/US1998/007353 WO1998046785A1 (en) 1997-04-15 1998-04-15 Dendritic cell hybrids

Publications (2)

Publication Number Publication Date
DE69839215D1 DE69839215D1 (de) 2008-04-17
DE69839215T2 true DE69839215T2 (de) 2009-03-19

Family

ID=21928022

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839215T Expired - Lifetime DE69839215T2 (de) 1997-04-15 1998-04-15 Dendritische zellhybride

Country Status (8)

Country Link
US (1) US6652848B1 (enExample)
EP (1) EP1007720B1 (enExample)
JP (2) JP2002501377A (enExample)
AT (1) ATE388237T1 (enExample)
AU (1) AU744042B2 (enExample)
CA (1) CA2286873C (enExample)
DE (1) DE69839215T2 (enExample)
WO (1) WO1998046785A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
AU2001238236B2 (en) * 1997-04-15 2007-02-15 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids
EP1071436A4 (en) * 1998-01-26 2003-08-27 Dana Farber Cancer Inst Inc IMMUNE EFFECTOR CELL HYBRIDS
US6389455B1 (en) * 1998-09-22 2002-05-14 Richard C. Fuisz Method and apparatus for bouncing electronic messages
EP1168924A4 (en) * 1999-03-31 2002-09-04 Univ Pittsburgh DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL
WO2001029193A2 (de) * 1999-10-22 2001-04-26 Peter Leskovar Zellkonstrukte, die für die immuntherapie geeignet sind, deren herstellung und verwendung
KR100363587B1 (ko) * 1999-11-12 2002-12-06 이시우 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US20090087450A1 (en) * 2000-01-11 2009-04-02 Greenville Hospital System Combination therapy of hybrid cells with BCG injection for treating Cancer Patients
US20070212338A1 (en) * 2000-01-11 2007-09-13 Greenville Hospital System Hybrid cells
DK1248836T3 (da) * 2000-01-11 2005-08-15 Greenville Hospital System Fremgangsmåde til fremstilling af vacciner ved anvendelse af hybridceller
EP1541675A3 (en) * 2000-01-11 2007-08-08 Greenville Hospital System Hybrid cells obtainable from antigen presenting cells
JP5054875B2 (ja) * 2000-02-11 2012-10-24 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 樹状細胞ハイブリッドによって活性化される細胞傷害性ｔリンパ球
WO2001062902A1 (en) * 2000-02-27 2001-08-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Hybrid cell vaccines
DE10009030A1 (de) * 2000-02-27 2001-09-20 Univ Eberhard Karls Impfstoff
DE10024384A1 (de) * 2000-05-17 2001-11-29 Mack Gerd R Herstellung von dendritischen Zellen aus Rückenmarkstammzellen
IL155514A0 (en) * 2000-10-20 2003-11-23 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
DE10139428A1 (de) * 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
JPWO2005083062A1 (ja) * 2004-02-26 2008-01-17 ジェノミディア株式会社 細胞ワクチン
JP2007528375A (ja) * 2004-03-02 2007-10-11 典也 大野 癌の治療および予防用雑種細胞ワクチンの方法および組成物
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2008005859A2 (en) 2006-06-30 2008-01-10 Baylor Research Institute Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells
CN109385400A (zh) * 2017-08-09 2019-02-26 科济生物医药（上海）有限公司 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
EP4319800A1 (en) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348878A (en) 1990-05-10 1994-09-20 Dana-Farber Cancer Institute Class I MHC-restricted T-T hybridomas, and a CD8-transfected BW5147, fusion partner therefor
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
JP3799413B2 (ja) * 1993-10-01 2006-07-19 スリーエム カンパニー 呼吸器マスクとともに使用する会話送信用アダプタ
EP0734440A1 (en) 1993-12-14 1996-10-02 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
WO1996007733A1 (en) 1994-09-09 1996-03-14 Zymogenetics, Inc. Preparation of immortalized cells
DE69634750T2 (de) 1995-03-31 2006-02-23 Université Libre de Bruxelles DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
WO1998017300A1 (en) * 1996-10-25 1998-04-30 Dana-Farber Cancer Institute, Inc. Mucin-mediated immunomodulation
EP1168924A4 (en) 1999-03-31 2002-09-04 Univ Pittsburgh DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL

Also Published As

Publication number Publication date
JP2002501377A (ja) 2002-01-15
CA2286873A1 (en) 1998-10-22
AU7112098A (en) 1998-11-11
US6652848B1 (en) 2003-11-25
DE69839215D1 (de) 2008-04-17
ATE388237T1 (de) 2008-03-15
EP1007720A4 (en) 2001-10-24
JP2008263997A (ja) 2008-11-06
EP1007720A1 (en) 2000-06-14
EP1007720B1 (en) 2008-03-05
CA2286873C (en) 2010-07-13
WO1998046785A1 (en) 1998-10-22
AU744042B2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
DE69839215T2 (de) Dendritische zellhybride
DE69718029T2 (de) Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
EP1311658B1 (de) Verfahren zur herstellung gebrauchsfertiger, antigenbeladener oder -unbeladener, kryokonservierter, reifer dendritischer zellen
DE69839273T2 (de) Krebsimmuntherapie mit semi-allogenen zellen
DE69328481T2 (de) In vitro bildung von dentritischen zellen
DE69729455T2 (de) Methode und zusammensetzungen zum erlangen reifer dendritischer zellen
DE60130130T2 (de) Zusammensetzungen und verfahren zur auslösung spezifischer zytolytischer t-zellantworten
DE69713336T2 (de) Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
DE60026166T2 (de) Vetozellen die wirksam in der prävention von transplantatabstossung sind und kein graft-versus-host potential aufweisen
DE69333433T2 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
Yang et al. Induction of alloreactive cytotoxic T cells by acute virus infection of mice.
McKinney et al. On the extraordinary capacity of allogeneic epidermal Langerhans cells to prime cytotoxic T cells in vivo.
DE69634750T2 (de) DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
DE60108661T2 (de) Herstellung und verwendung von dendritischen zellen
DE69414572T2 (de) Immortalisierung von dendritischen zellen mit dem v-myc onkogen
DE69734989T2 (de) Antigenpräsentierende zellen, ein verfahren zur deren herstellung und deren verwendung als zelluläre impfstoffen
US20090081127A1 (en) Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
DE60130634T2 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
DE4410136A1 (de) Tumorizide T-Lymphozyten
AT412145B (de) Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
JP2003521936A5 (enExample)
DE60130206T2 (de) Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen
Lambert et al. Characterization of the antigen-presenting cell and T cell requirements for induction of pulmonary eosinophilia in a murine model of asthma
WO2003045428A2 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
DE69835615T2 (de) Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition